Insomnia medication
PreclinicalSmall molecule
Insomnia medication is one of 50 small molecule programs targeting Acute Myocardial Infarction. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
75 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Plavix
SanofiApproved
Repatha
AmgenApproved
Eliquis
Bristol-Myers SquibbApproved
Radicava
ShionogiApproved
Avapro
SanofiApproved
Onglyza
AstraZenecaApproved
Leqvio
NovartisApproved
Angiomax
BBaxter Healthcare Corporation
Approved
Aggrastat
MMedicure
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Insomnia medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSamsung Medical Center